FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment

Boston-based Ve­rastem On­col­o­gy on Thurs­day won ac­cel­er­at­ed ap­proval from the FDA for Avmap­ki Fakzyn­ja as a sec­ond-line treat­ment for adult pa­tients with KRAS-mu­tat­ed re­cur­rent low …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER